HR
HROW.US Harrow Health Inc
- Market cap
- USD 1.13B
- P/E
- -
- P/B
- 38.73x
- ROE
- -160.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HROW.US undervalued?
Graham numberThe Graham number of Harrow Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Harrow Health Inc fundamental analysis
No fundamental analysis for Harrow Health Inc yet.
Harrow Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; I…
Full company profileHarrow Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Harrow Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.9M | 26.8M | 41.4M | 51.2M | 48.9M | 72.5M | 88.6M | 130M | 200M | 272M | 286M |
| Gross Profit | 10.1M | 13.3M | 24.9M | 34.4M | 34.4M | 54.3M | 63.2M | 90.6M | 150M | 204M | 203M |
| Operating Income | -15.9M | -12.2M | -5.22M | -4.80M | 385K | 1.61M | 1.92M | 431K | 8.82M | 38.6M | -28.8M |
| EBITDA | -14.2M | -10.4M | -3.37M | 1.91M | 3.49M | 5.76M | -3.10M | 13.2M | 23.6M | 42.1M | -5.11M |
| Net Income | -19.1M | -12.0M | 14.6M | 168K | -3.36M | -18.0M | -14.1M | -24.4M | -17.5M | -5.14M | -46.8M |
| EPS | -1.50 | -0.60 | 0.61 | 0.01 | -0.13 | -0.67 | -0.51 | -0.75 | -0.49 | -0.14 | -1.22 |
| Balance Sheet | |||||||||||
| Total Assets | 27.2M | 23.9M | 49.5M | 59.1M | 57.5M | 98.3M | 157M | 312M | 389M | 399M | 443M |
| Total Liabilities | 20.8M | 21.3M | 24.7M | 31.7M | 30.6M | 87.4M | 130M | 242M | 320M | 347M | 414M |
| Shareholders' Equity | 6.43M | 2.62M | 24.8M | 27.7M | 27.2M | 11.3M | 26.9M | 70.4M | 69.7M | 52.4M | 29.2M |
| Cash & Short-term Investments | 8.85M | 4.02M | 28.1M | 29.9M | 32.7M | 50.7M | 96.3M | 82.8M | 47.2M | 72.9M | 75.3M |
| Total Debt | 13.7M | 15.3M | 15.2M | 21.0M | 23.5M | 78.0M | 105M | 191M | 229M | 252M | 301M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.2M | -8.80M | 687K | 950K | -1.10M | 5.08M | 1.71M | 3.84M | -22.2M | 43.9M | -36.5M |
| Capital Expenditure | 7.14M | 1.07M | 2.20M | 1.84M | 994K | 28.5M | 7.77M | 153M | 38.7M | 1.10M | 1.02M |
| Free Cash Flow | -18.4M | -9.88M | -1.52M | -887K | -2.09M | -23.4M | -6.07M | -149M | -60.9M | 42.8M | -37.0M |
| Ratios | |||||||||||
| ROE | -296.8% | -458.3% | 59.1% | 0.6% | -12.3% | -159.6% | -52.4% | -34.7% | -25.1% | -9.8% | -160.4% |
| ROA | -70.1% | -50.1% | 29.6% | 0.3% | -5.8% | -18.3% | -9.0% | -7.8% | -4.5% | -1.3% | -10.6% |
| Net Profit Margin | -95.7% | -44.8% | 35.3% | 0.3% | -6.9% | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% | -16.4% |
| Debt to Equity | 2.13x | 5.86x | 0.62x | 0.76x | 0.87x | 6.91x | 3.90x | 2.71x | 3.29x | 4.80x | 10.31x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Harrow Health Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 876K | 0.03 | - |
| 2021 | USD 127K | 0.00 | - |
| 2020 | USD 58.0K | 0.00 | - |
| 2019 | USD 127K | 0.00 | 75.6% |
| 2018 | USD 127K | 0.01 | 0.9% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Feb 8, 2013.
Who owns Harrow Health Inc
- Insiders 15.56%
- Institutions 60.57%
- Public & others 23.87%
- Shares outstanding 37.5M
- Free float 28.3M
Top funds holding HROW.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.00M | 2.67% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 814K | 2.17% | 0.00% | Oct 2026 |
| Baron Discovery Institutional | 715K | 1.91% | +24.11% | Sep 2026 |
| Janus Henderson Venture D | 470K | 1.25% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 354K | 0.94% | +0.18% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 302K | 0.81% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 277K | 0.74% | +0.27% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 246K | 0.66% | +2.88% | Oct 2026 |
| Putnam Global Health Care A | 210K | 0.56% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 188K | 0.50% | +1.24% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 170K | 0.45% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 151K | 0.40% | -7.56% | Sep 2026 |
| JNL Multi-Manager Small Cap Growth A | 148K | 0.40% | +23.60% | Sep 2026 |
| DFA U.S. Small Cap I | 148K | 0.40% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 126K | 0.34% | 0.00% | Oct 2026 |
| Private Capital Management Value I | 126K | 0.34% | 0.00% | Jun 2026 |
| DFA US Micro Cap I | 126K | 0.34% | 0.00% | Sep 2026 |
| iShares US Pharmaceuticals ETF | 108K | 0.29% | +0.33% | Oct 2026 |
| Principal US Small Cap ETF | 104K | 0.28% | +0.05% | Oct 2026 |
| iShares Micro-Cap ETF | 98.1K | 0.26% | 0.00% | Oct 2026 |
Top institutions holding HROW.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.74M | 7.30% | +7.34% | Jun 2026 |
| Opaleye Management Inc | 2.40M | 6.40% | -15.26% | Jun 2026 |
| Private Capital Management, LLC | 1.60M | 4.26% | +2.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.42M | 3.78% | +1.01% | Jun 2026 |
| Deep Track Capital, LP | 969K | 2.58% | 0.00% | Jun 2026 |
| State Street Corp | 940K | 2.50% | +9.92% | Jun 2026 |
| Geode Capital Management, LLC | 906K | 2.41% | +6.28% | Jun 2026 |
| BAMCO Inc | 809K | 2.16% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 722K | 1.92% | +8.21% | Sep 2026 |
| Jupiter Topco LLC | 579K | 1.54% | 0.00% | Jun 2026 |
| Divisadero Street Capital Management, LP | 439K | 1.17% | 0.00% | Jun 2026 |
| Rice Hall James & Associates, LLC | 388K | 1.03% | +5.26% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 369K | 0.98% | -42.72% | Jun 2026 |
| Citadel Advisors Llc | 360K | 0.96% | +62.65% | Jun 2026 |
| Northern Trust Corp | 323K | 0.86% | +8.87% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 320K | 0.85% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 319K | 0.85% | +10.29% | Jun 2026 |
| Charles Schwab Investment Management Inc | 274K | 0.73% | +1.17% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 235K | 0.63% | +3.43% | Jun 2026 |
| Westside Investment Management, Inc. | 224K | 0.60% | +20.51% | Jun 2026 |
Harrow Health Inc company profile
- Company name
- Harrow Health Inc
- Ticker
- HROW.US
- Exchange
- USA Stocks
- Listed since
- Sep 28, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 373
- Fiscal year end
- December
- Address
- 1A Burton Hills Boulevard, Nashville, TN, United States, 37215
- Phone
- 615 733 4730
- Website
- harrow.com
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Harrow Health Inc management
10- Mr. Mark L. Baum J.D.CEO, Chairman of the Board & Founder · born 1972
- Mr. Andrew R. Boll C.F.A., C.M.A.President, CFO & Chief Accounting Officer · born 1982
- Dr. Amir W. Shojaei Ph.D., Pharm.D.Chief Scientific Officer · born 1968
- Mr. Francis W. MulleryPresident & CEO of Harrow's ImprimisRx Division
- Mr. Michael D. BiegaVice President of Investor Relations & Communications
- Mr. Brett A. BurrellVice President of Legal & Compliance
- Ms. Kim BarrattChief Talent Officer
- Dr. Mark A. Mannebach Ph.D., R.Ph.Head of Regulatory Affairs & Pharmacovigilance
- Dr. Prashanth S. AnnavajjhalaChief of Staff
- Mr. Patrick W. SullivanChief Commercial Officer · born 1976